Information Provided By: 
Fly News Breaks for March 6, 2018
MYL
Mar 6, 2018 | 07:28 EDT
As previously reported, Morgan Stanley analyst David Risinger upgraded Mylan to Overweight from Equal Weight as he believes the company is well positioned to gain U.S. generics share relative to competitors and he expects investor enthusiasm for its large biosimilar pipeline to rise over time. Given his higher confidence in Mylan's earnings prospects and ability to execute on its pipeline, Risinger raised his FY18 EPS estimate by 4%, his FY19 forecast by 9% and his FY20 view by 12%. He also increased his price target on the stock to $50 from $39.
News For MYL From the Last 2 Days
There are no results for your query MYL
